London, Feb 16, 2026, 09:18 GMT — Regular session
- Haleon shares down about 0.8% in early London trading
- Full-year 2025 results due Feb. 25, with guidance in focus
- Stock still sits close to its 12-month high
Haleon PLC shares fell on Monday, with the consumer health group down 0.8% at 405.8 pence by 0918 GMT in London. (Investing)
The drift lower comes with a clear marker on the calendar: Haleon is due to publish full-year results next week. The stock has been trading within reach of its 12-month highs, leaving less room for surprises.
Investors are looking for anything that changes the near-term read on growth, pricing and costs, after a quiet stretch for company-specific news. Monday’s move was modest, but it sets the tone going into a busy week for UK reporting.
The shares opened at 405.5 pence, versus a previous close of 409.2 pence on Friday, with more than 24 million shares traded so far, London Stock Exchange data showed. (London Stock Exchange)
In New York, Haleon’s ADR was last at $11.20, up about 0.3% from the previous close, according to market data.
Haleon’s investor calendar shows full-year 2025 results due on Feb. 25, followed by a first-quarter trading update on April 29. (Haleon Corporate)
Management has also flagged organisational changes ahead of the numbers. In a January update, Haleon said it was evolving its operating model to “drive growth” and make the business “simpler and more agile,” and that more detail would come with the Feb. 25 results. (Haleon Corporate)
For traders, the questions are familiar: whether volumes hold up as pricing eases, and how much margin the group can protect while still spending behind brands such as Sensodyne, Advil and Centrum.
But there is a risk the update disappoints. Any softer-than-expected guidance, slower delivery on efficiency plans, or signs that consumers are trading down could put pressure on a stock that has already moved up sharply over the past year.
